- Home
- APLT vs PGRE Comparison
APLT vs PGRE Comparison
Compare APLT & PGRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- PGRE
- Stock Information
- Founded
- APLT 2016
- PGRE 1978
- Country
- APLT United States
- PGRE United States
- Employees
- APLT N/A
- PGRE N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- PGRE Real Estate Investment Trusts
- Sector
- APLT Health Care
- PGRE Real Estate
- Exchange
- APLT Nasdaq
- PGRE Nasdaq
- Market Cap
- APLT 42.5M
- PGRE 1.3B
- IPO Year
- APLT 2019
- PGRE 2014
- Fundamental
- Price
- APLT $0.33
- PGRE $6.02
- Analyst Decision
- APLT Buy
- PGRE Hold
- Analyst Count
- APLT 7
- PGRE 4
- Target Price
- APLT $6.10
- PGRE $5.38
- AVG Volume (30 Days)
- APLT 2.1M
- PGRE 2.8M
- Earning Date
- APLT 08-06-2025
- PGRE 07-30-2025
- Dividend Yield
- APLT N/A
- PGRE N/A
- EPS Growth
- APLT N/A
- PGRE N/A
- EPS
- APLT N/A
- PGRE N/A
- Revenue
- APLT $265,000.00
- PGRE $711,729,000.00
- Revenue This Year
- APLT $1,768.13
- PGRE $2.74
- Revenue Next Year
- APLT $292.85
- PGRE N/A
- P/E Ratio
- APLT N/A
- PGRE N/A
- Revenue Growth
- APLT N/A
- PGRE 49.28
- 52 Week Low
- APLT $0.30
- PGRE $3.75
- 52 Week High
- APLT $10.62
- PGRE $6.62
- Technical
- Relative Strength Index (RSI)
- APLT 42.58
- PGRE 54.79
- Support Level
- APLT $0.30
- PGRE $6.01
- Resistance Level
- APLT $0.39
- PGRE $6.49
- Average True Range (ATR)
- APLT 0.03
- PGRE 0.16
- MACD
- APLT 0.00
- PGRE -0.10
- Stochastic Oscillator
- APLT 21.64
- PGRE 22.99
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.